Harvard Bioscience (HBIO) Inventory (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Inventory data on file, last reported at $22.2 million in Q1 2026.

• Quarterly Inventory fell 2.68% year-over-year to $22.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.2 million (down 2.68% YoY) and the FY2025 annual result came in at $20.8 million, down 10.5% from the prior year.
• Inventory rose to $22.2 million in Q1 2026 per HBIO's latest filing, from $20.8 million in the prior quarter.
• Across five years, Inventory topped out at $29.3 million in Q2 2022 and bottomed at $20.8 million in Q4 2025.
• The 5-year median for Inventory is $25.1 million (2024), against an average of $24.8 million.
• The widest annual swing landed in 2022, when Inventory grew 26.61%; it then slipped 16.88% in 2025.
• Tracing HBIO's Inventory over 5 years: stood at $26.4 million in 2022, then declined by 6.52% to $24.7 million in 2023, then slipped by 5.95% to $23.2 million in 2024, then retreated by 10.5% to $20.8 million in 2025, then rose by 6.73% to $22.2 million in 2026.
• Per Business Quant, the three latest HBIO Inventory figures stand at $22.2 million (Q1 2026), $20.8 million (Q4 2025), and $21.6 million (Q3 2025).

Peer Comparison